(Q40304351)

19 September 2017

title

Management of acute decompensated heart failure: treatment, controversy, and future directions (English)

1 reference

acute decompensated heart failure

19 September 2017

main subject

1 reference

Mark A Munger

1

1 reference

19 September 2017

language of work or name

English

0 references

publication date

1 August 2006

1 reference

19 September 2017

1 reference

19 September 2017

volume

26

1 reference

19 September 2017

issue

8 Pt 2

1 reference

19 September 2017

page(s)

131S-138S

1 reference

The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8PART2.131S

Economics of chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8PART2.131S

Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8PART2.131S

Optimizing therapy for complex or refractory heart failure: a management algorithm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8PART2.131S

Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8PART2.131S

Aldosterone as a mediator in cardiovascular injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8PART2.131S

Hepatic dysfunction after left ventricular mechanical assist in patients with end-stage heart failure: role of inflammatory response and hepatic microcirculation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8PART2.131S

Tailored therapy to hemodynamic goals for advanced heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8PART2.131S

In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8PART2.131S

Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8PART2.131S

Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8PART2.131S

Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8PART2.131S

BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8PART2.131S

Early ultrafiltration in patients with decompensated heart failure and diuretic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8PART2.131S

The development of positive inotropic agents for chronic heart failure: how have we gone astray?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8PART2.131S

Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8PART2.131S

Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8PART2.131S

Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8PART2.131S

Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8PART2.131S

Cardiac fibrosis in mice lacking brain natriuretic peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8PART2.131S

Ventricular production of natriuretic peptides and ventricular structural remodeling in hypertensive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8PART2.131S

Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8PART2.131S

Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8PART2.131S

Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8PART2.131S

The prognostic importance of different definitions of worsening renal function in congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8PART2.131S

Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8PART2.131S

Role of the natriuretic peptide system in cardiorenal protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8PART2.131S

Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8PART2.131S

Elevations in serum creatinine concentration: concerning or reassuring?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8PART2.131S

Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8PART2.131S

Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8PART2.131S

Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8PART2.131S

Effects of levosimendan and milrinone on oxygen consumption in isolated guinea-pig heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8PART2.131S

Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8PART2.131S

The renal urodilatin system: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8PART2.131S

Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a double-blind, placebo-controlled, ascending-dose trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8PART2.131S

10.1592/PHCO.26.8PART2.131S

21 January 2018

Identifiers

DOI

1 reference

19 September 2017

1 reference